Investment and innovation in drug research and development (RD) for highly prevalent chronic diseases has stalled in recent decades, despite half of all Americans living with at least one chronic disease. As a result, prevalent chronic diseases are producing immense health care costs as well as preventable suffering and death. On February 22, March 2, and March 8, 2021, the National Academies of Sciences, Engineering, and Medicine, convened a workshop to discuss barriers to innovation in this space and examine strategies and incentives to support equitable, person-centered drug RD for prevalent chronic diseases.
Sprache
ISBN-13
978-0-309-09239-5 (9780309092395)
Schweitzer Klassifikation
